Company Description
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States.
The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19.
It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses.
The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022.
Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
| Country | United States |
| Founded | 2020 |
| IPO Date | Aug 6, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 95 |
| CEO | William Duke |
Contact Details
Address: 1601 Trapelo Road, Suite 178 Waltham, Massachusetts 02451 United States | |
| Phone | 781 819 0080 |
| Website | invivyd.com |
Stock Details
| Ticker Symbol | IVVD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001832038 |
| CUSIP Number | 00534A102 |
| ISIN Number | US00534A1025 |
| Employer ID | 85-1403134 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert D. Allen Ph.D. | Chief Scientific Officer |
| Jill Andersen J.D. | Chief Legal Officer and Corporate Secretary |
| William E. Duke Jr., M.B.A. | Chief Financial Officer and Principal Executive Officer |
| Stacy Price M.S. | Chief Technology and Manufacturing Officer |
| Scott Young | Senior Vice President of Investor Relations and Corporate Communications |
| Julie Green M.B.A. | Chief Human Resources Officer |
| Dr. Mark A. Wingertzahn Ph.D. | Senior Vice President of Clinical Development and Medical Affairs |
| Timothy Lee | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | 10-Q | Quarterly Report |
| Nov 14, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 8, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Oct 29, 2024 | 8-K | Current Report |
| Sep 23, 2024 | 8-K | Current Report |
| Sep 6, 2024 | 8-K | Current Report |
| Sep 4, 2024 | 8-K | Current Report |